Inhibikase Therapeutics, Inc. Investing Cash Flow
Inhibikase Therapeutics, Inc. (IKT) reported Investing Cash Flow of -$86.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$5.91M, a 160.02% decline year-over-year.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$80.48M, a 482.27% decline year-over-year.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$98.85K.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$28.75M, a 1237.96% decline year-over-year.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $2.05M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$37.00M, a 417.45% decline from fiscal 2023.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $11.66M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$16.01M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$86.39M 10-Q · filed 2026-08-11 | -$86.49M derived: sum of 3 quarters · filed 2026-08-11 | -$115.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$80.48M 10-Q · filed 2026-05-12 | -$80.58M derived: sum of 2 quarters · filed 2026-05-12 | -$109.33M derived: sum of 3 quarters · filed 2026-05-12 | -$99.49M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$98.85K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$28.84M derived: sum of 2 quarters · filed 2026-03-26 | -$19.00M derived: sum of 3 quarters · filed 2026-08-11 | $2.05M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$28.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$18.90M derived: sum of 2 quarters · filed 2026-08-11 | $2.15M 10-Q · filed 2025-11-14 | -$36.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $9.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $30.90M 10-Q · filed 2026-08-11 | -$7.86M derived: sum of 3 quarters · filed 2026-08-11 | -$5.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $21.05M 10-Q · filed 2026-05-12 | -$17.71M derived: sum of 2 quarters · filed 2026-05-12 | -$15.18M derived: sum of 3 quarters · filed 2026-05-12 | -$12.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$38.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$36.24M derived: sum of 2 quarters · filed 2026-03-26 | -$33.69M derived: sum of 3 quarters · filed 2026-03-26 | -$37.00M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.07M derived: sum of 2 quarters · filed 2025-11-14 | $1.76M 10-Q · filed 2025-11-14 | -$358.07K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$768.59K 10-Q · filed 2025-08-14 | -$2.88M derived: sum of 3 quarters · filed 2025-08-14 | $14.18M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$3.31M 10-Q · filed 2025-05-14 | -$5.43M derived: sum of 2 quarters · filed 2025-05-14 | $11.63M derived: sum of 3 quarters · filed 2025-05-14 | $14.18M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $14.95M derived: sum of 2 quarters · filed 2025-03-27 | $17.50M derived: sum of 3 quarters · filed 2025-03-27 | $11.66M 10-K · filed 2025-03-27 |
| 2023-09-30 | $17.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $19.61M derived: sum of 2 quarters · filed 2024-11-14 | $13.77M 10-Q · filed 2024-11-14 | $18.74M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$3.29M 10-Q · filed 2024-08-14 | $1.67M derived: sum of 3 quarters · filed 2024-08-14 | -$19.25M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$5.84M 10-Q · filed 2024-05-15 | -$875.83K derived: sum of 2 quarters · filed 2024-05-15 | -$21.80M derived: sum of 3 quarters · filed 2024-05-15 | -$21.84M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$15.96M derived: sum of 2 quarters · filed 2024-03-27 | -$16.01M derived: sum of 3 quarters · filed 2024-03-27 | -$16.01M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$20.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$20.97M derived: sum of 2 quarters · filed 2023-11-14 | -$20.97M 10-Q · filed 2023-11-14 | -$20.97M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$43.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$43.09K 10-Q · filed 2023-08-14 | -$43.09K derived: sum of 3 quarters · filed 2023-08-14 | -$43.09K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | $0.00 derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |